Advertising of contrast material: A developing problem

Problems exist when indications for the use of new contrast agents and new indications for the use of conventional contrast agents are considered in relation to advertisements. Ultimately, the consumer pays the cost of expensive FDA testing, often to prove what is already obvious. Other medically indicated uses of a contrast agent may remain unapproved because there is no financial incentive to seek approval, and needed modifications in already approved advertisements may not be sought for the same reason. A cooperative effort among manufacturers, radiologists, and the FDA is needed to improve the process.